Wanyin Wu

2.2k total citations · 1 hit paper
49 papers, 1.6k citations indexed

About

Wanyin Wu is a scholar working on Molecular Biology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Wanyin Wu has authored 49 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 16 papers in Cancer Research and 13 papers in Pathology and Forensic Medicine. Recurrent topics in Wanyin Wu's work include Cancer Mechanisms and Therapy (13 papers), Cancer-related molecular mechanisms research (11 papers) and MicroRNA in disease regulation (10 papers). Wanyin Wu is often cited by papers focused on Cancer Mechanisms and Therapy (13 papers), Cancer-related molecular mechanisms research (11 papers) and MicroRNA in disease regulation (10 papers). Wanyin Wu collaborates with scholars based in China, United States and Hong Kong. Wanyin Wu's co-authors include Sumei Wang, Shunqin Long, Swei Sunny Hann, François X. Claret, Qing Tang, Jingjing Wu, Xiaojuan Li, Yun Chen, Ling Han and Tang Qing and has published in prestigious journals such as Oncogene, Frontiers in Immunology and Journal of Ethnopharmacology.

In The Last Decade

Wanyin Wu

47 papers receiving 1.6k citations

Hit Papers

The role of PD-1/PD-L1 and application of immune-checkpoi... 2022 2026 2023 2024 2022 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
    2022 313 citations Shunqin Long, Yaya Yu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wanyin Wu China 21 868 496 405 249 200 49 1.6k
Sheng Liu China 24 960 1.1× 380 0.8× 393 1.0× 174 0.7× 222 1.1× 132 1.8k
Lihong Zhou China 24 1.3k 1.5× 743 1.5× 505 1.2× 139 0.6× 236 1.2× 55 2.1k
Baojin Hua China 19 641 0.7× 266 0.5× 327 0.8× 271 1.1× 159 0.8× 38 1.3k
Oluwaseun Adebayo Bamodu Taiwan 28 1.1k 1.3× 569 1.1× 468 1.2× 208 0.8× 196 1.0× 67 2.0k
Maolan Li China 30 1.4k 1.6× 767 1.5× 608 1.5× 411 1.7× 133 0.7× 102 2.5k
Zhifei Cao China 23 791 0.9× 361 0.7× 306 0.8× 120 0.5× 162 0.8× 54 1.4k
Xiangsong Wu China 30 1.6k 1.8× 914 1.8× 568 1.4× 329 1.3× 148 0.7× 74 2.5k
Yongheng Bai China 26 990 1.1× 254 0.5× 331 0.8× 182 0.7× 254 1.3× 74 1.9k
Chun‐Yin Huang Taiwan 30 1.2k 1.4× 411 0.8× 463 1.1× 135 0.5× 321 1.6× 60 2.2k
Sung‐Jig Lim South Korea 24 766 0.9× 310 0.6× 387 1.0× 199 0.8× 222 1.1× 69 1.7k

Countries citing papers authored by Wanyin Wu

Since Specialization
Citations

This map shows the geographic impact of Wanyin Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wanyin Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wanyin Wu more than expected).

Fields of papers citing papers by Wanyin Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wanyin Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wanyin Wu. The network helps show where Wanyin Wu may publish in the future.

Co-authorship network of co-authors of Wanyin Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Wanyin Wu. A scholar is included among the top collaborators of Wanyin Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wanyin Wu. Wanyin Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Jixin, et al.. (2025). Risk factors for brain metastasis in lung cancer: an umbrella review of systematic reviews and meta-analyses. BMJ Open. 15(1). e087181–e087181. 1 indexed citations
2.
Xu, Chunyan, Rui Wang, Qing Tang, et al.. (2024). Treating human cancer by targeting EZH2. Genes & Diseases. 12(3). 101313–101313. 6 indexed citations
3.
Tang, Qing, Xiaobing Yang, Rui Wang, et al.. (2024). Reprogramming of glucose metabolism: The hallmark of malignant transformation and target for advanced diagnostics and treatments. Biomedicine & Pharmacotherapy. 178. 117257–117257. 18 indexed citations
4.
Chen, Jixin, et al.. (2023). The application of arsenic trioxide in cancer: An umbrella review of meta-analyses based on randomized controlled trials. Journal of Ethnopharmacology. 316. 116734–116734. 8 indexed citations
5.
Wang, Rui, Zhiming Zhu, Sheng Wang, et al.. (2023). Kaempferol promotes non-small cell lung cancer cell autophagy via restricting Met pathway. Phytomedicine. 121. 155090–155090. 33 indexed citations
6.
Chen, Jixin, et al.. (2023). The complementary and alternative roles of elemene injection in cancer: An umbrella review. Pharmacological Research. 198. 107007–107007. 12 indexed citations
7.
Tang, Qing, Shunqin Long, Yaya Yu, et al.. (2023). FZKA reverses gefitinib resistance by regulating EZH2/Snail/EGFR signaling pathway in lung adenocarcinoma. Journal of Ethnopharmacology. 318(Pt A). 116646–116646. 7 indexed citations
8.
Chen, Jixin, Shuqi Chen, Xiaobing Yang, Sumei Wang, & Wanyin Wu. (2022). Efficacy and safety of Brucea javanica oil emulsion injection as adjuvant therapy for cancer: An overview of systematic reviews and meta-analyses. Phytomedicine. 102. 154141–154141. 21 indexed citations
9.
Gong, Li, et al.. (2021). Compound Kushen Injection Protects Skin From Radiation Injury via Regulating Bim. Frontiers in Pharmacology. 12. 753068–753068. 8 indexed citations
10.
Wang, Sumei, Do‐Youn Oh, Vasiliki Leventaki, et al.. (2019). MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer. Cancer Letters. 465. 12–23. 26 indexed citations
11.
Wang, Sumei, François-Xavier Claret, & Wanyin Wu. (2019). MicroRNAs as Therapeutic Targets in Nasopharyngeal Carcinoma. Frontiers in Oncology. 9. 756–756. 42 indexed citations
12.
13.
14.
15.
Wang, Sumei, Yunbao Pan, Tong Xu, et al.. (2016). Hsa-miR-24-3p increases nasopharyngeal carcinoma radiosensitivity by targeting both the 3′UTR and 5′UTR of Jab1/CSN5. Oncogene. 35(47). 6096–6108. 70 indexed citations
16.
Li, Longmei, Sumei Wang, Fang Zheng, Wanyin Wu, & Swei Sunny Hann. (2016). Chinese herbal medicine Fuzheng Kang-Ai decoction sensitized the effect of gefitinib on inhibition of human lung cancer cells through inactivating PI3-K/Akt -mediated suppressing MUC1 expression. Journal of Ethnopharmacology. 194. 918–929. 16 indexed citations
17.
Wu, Jingjing, Shunyu Zhao, Qing Tang, et al.. (2015). Activation of SAPK/JNK mediated the inhibition and reciprocal interaction of DNA methyltransferase 1 and EZH2 by ursolic acid in human lung cancer cells. Journal of Experimental & Clinical Cancer Research. 34(1). 99–99. 31 indexed citations
18.
Wu, Wanyin, et al.. (2014). Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: A retrospective case–control study. Complementary Therapies in Medicine. 22(6). 1010–1018. 40 indexed citations
19.
Wu, Wanyin. (2013). Distribution Characteristics of Syndrome Types in TCM in Patients with Advanced Non-Small Cell Lung Cancer(NSCLC). Liaoning Zhongyiyao Daxue xuebao. 2 indexed citations
20.
Wu, Wanyin. (2011). TCM Syndrome in 121 Cases of IIIB/IV Non-small Cell Lung Cancer. Liaoning zhongyi zazhi.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sheng Liu Breakdown of academic impact, for papers by Lihong Zhou Breakdown of academic impact, for papers by Baojin Hua Breakdown of academic impact, for papers by Oluwaseun Adebayo Bamodu Breakdown of academic impact, for papers by Maolan Li Breakdown of academic impact, for papers by Zhifei Cao Breakdown of academic impact, for papers by Xiangsong Wu Breakdown of academic impact, for papers by Yongheng Bai Breakdown of academic impact, for papers by Chun‐Yin Huang Breakdown of academic impact, for papers by Sung‐Jig Lim
Rankless by CCL
2026